Replimune Group (REPL) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
5 Jan, 2026Opening remarks and agenda
Meeting commenced with a welcome and introduction of the Executive Chairman and key legal and accounting representatives.
Attendees were informed about the process for submitting questions and the meeting's official business scope.
The agenda included legal formalities, introduction of officers and directors, and a description of matters for shareholder consideration.
Board and executive committee updates
Introductions were made for all directors and key officers, including the CEO, Lead Independent Director, and CFO.
Overview of voting outcomes
Kapil Dhingra, Christy Oliger, Joseph Slattery, Mike Goller, and Philip Astley-Sparke were elected as Class I Directors to serve until the 2028 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent public accountants for fiscal year ending March 31, 2026, was approved.
Non-binding advisory approval of named executive officer compensation was passed.
Amendment to the 2018 Omnibus Incentive Plan was not approved.
Latest events from Replimune Group
- Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress.REPL
Leerink Global Healthcare Conference 20269 Mar 2026 - Net loss rose to $70.9M, FDA review of RP1 advances, and cash runway extends into Q1 2027.REPL
Q3 20263 Feb 2026 - 33.6% ORR and durable responses seen in anti-PD1 failed melanoma with favorable safety.REPL
Study Result2 Feb 2026 - RP1 and RP2 show strong efficacy in tough cancers, with regulatory and commercial progress ongoing.REPL
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Oncolytic immunotherapy nears launch with strong efficacy and broad pipeline expansion.REPL
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Durable responses, safety, and commercial readiness support a 2025 launch and pipeline growth.REPL
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Up to $250M in securities, including $100M ATM, to fund late-stage cancer immunotherapy pipeline.REPL
Registration Filing16 Dec 2025 - Late-stage oncolytic immunotherapy programs advance after $100M private placement and share resale registration.REPL
Registration Filing16 Dec 2025 - Biotech firm registers 25M+ shares for resale amid late-stage cancer trial progress.REPL
Registration Filing16 Dec 2025